ADC Therapeutics (ADCT) Long-Term Deferred Tax (2021 - 2023)

ADC Therapeutics (ADCT) has reported Long-Term Deferred Tax for 3 consecutive years, with $35.4 million the latest figure, recorded in Q3 2023.

• Quarterly Long-Term Deferred Tax rose 5.36% year-over-year to $35.4 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $35.4 million (up 5.36% YoY) and the FY2022 annual result came in at $37.1 million, up 42.44% from the prior year.
• Long-Term Deferred Tax climbed to $35.4 million in Q3 2023 per ADCT's latest filing, from $34.8 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for ADCT reached as high as $37.1 million in Q4 2022 and fell as low as $26.0 million in Q4 2021.
• A 3-year average of $32.3 million and a median of $33.8 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax jumped 42.44% — and 2023, when it decreased 7.69%.
• Year by year, Long-Term Deferred Tax stood at $26.0 million in 2021, then surged by 42.44% to $37.1 million in 2022, then fell by 4.59% to $35.4 million in 2023.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $35.4 million, $34.8 million, and $27.6 million for Q3 2023, Q2 2023, and Q1 2023 respectively.